Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions.

In the open-label extension phase, tafamidis showed a trend toward reduced all-cause mortality in octogenarians at 60 months, with a median survival of 45 vs. 27 months in continuous tafamidis and placebo to tafamidis arms, respectively [ 19 ].

also in 53,322 other papers